Opko Health, Inc.

Regeneron to Acquire 23andMe for $256 Million, Expanding Genetics-Driven Drug Discovery Capabilities

3 days ago

• Regeneron Pharmaceuticals has won the bankruptcy auction for 23andMe's assets with a $256 million bid, aiming to maintain the consumer genetics service while enhancing its drug discovery platform. • The acquisition includes 23andMe's Personal Genome Service, Total Health, Research Services, and Biobank assets, but excludes the Lemonaid Health business. • Regeneron has committed to prioritizing privacy and ethical use of customer data, working with a court-appointed Customer Privacy Ombudsman to ensure compliance with existing policies.

OPKO Health and Entera Bio Collaborate to Develop First Oral GLP-1/Glucagon Dual Agonist for Obesity Treatment

2 months ago

• OPKO Health and Entera Bio have formed a collaboration to advance the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet for obesity, metabolic and fibrotic disorders. • The partnership combines OPKO's proprietary long-acting oxyntomodulin analog with Entera's N-Tab™ technology, with an IND application expected to be filed with the FDA later this year. • Under the agreement, OPKO will hold 60% ownership and Entera 40%, with OPKO investing $8 million in Entera shares to fund development through Phase 1 clinical trials.

Entera Bio Announces Positive Updates on Oral Peptide Programs and Q3 2024 Financial Results

6 months ago

• Entera Bio's EB613, an oral PTH(1-34) tablet for post-menopausal women with osteoporosis, shows promising comparative pharmacological data presented at ASBMR 2024. • Topline results for the oral oxyntomodulin (OXM) tablet program, a GLP-1/glucagon agonist for obesity, demonstrate significant systemic exposure and glucose reduction. • Entera Bio is advancing its oral GLP-2 tablet for Short Bowel Syndrome and EB612 for hypoparathyroidism, both in collaboration with partners. • The company's cash and cash equivalents totaled $6.9 million as of September 30, 2024, expected to fund operations into the third quarter of 2025.

Entera Bio and OPKO Health Announce Positive PK/PD Results for Oral Oxyntomodulin for Obesity and Metabolic Disorders

8 months ago

• Entera Bio and OPKO Health reported positive pharmacokinetic/pharmacodynamic (PK/PD) results for their oral oxyntomodulin (OXM) tablet candidate targeting obesity and metabolic disorders. • In vivo studies in rodent and pig models demonstrated significant systemic exposure and favorable bioavailability of oral OXM following a single dose. • Oral OXM significantly reduced plasma glucose levels in rats post-glucose administration compared to placebo, indicating potential pharmacologic effect. • The companies plan to present the data at an upcoming clinical conference and advance the program toward IND-enabling efforts.